The remarkable efficacy of new diabetes and weight loss medicines like Ozempic and Mounjaro have been one of the biggest health stories of recent years. Despite rising rates of diabetes and obesity, ...

Donald Trump 's renewed push to take control of Greenland is setting off a high-stakes showdown with Denmark, a small country ...

The GLP-1 receptor agonist exenatide failed to meet its primary outcome in a phase III trial of Parkinson's disease patients.

As Eli Lilly ends the year with Zepbound in good supply, TD Cowen analyst Steve Scaliaasked CEO David Ricks if the company ...

Ozempic has been approved to reduce the risk of worsening kidney disease and cardiovascular death in adults with Type 2 ...

Nephrologists jumped on the GLP-1 bandwagon well before Novo Nordisk won FDA approval for Ozempic in chronic kidney disease ...

Weight-loss jabs, such as Ozempic, Wegovy and Mounjaro, have quickly earned a glowing global reputation for shifting the ...

Scientists remain puzzled as to why some individuals taking popular weight loss and diabetes medications such as Ozempic and ...

In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...

While popular drugs like Ozempic and Wegovy are only available as injections, drugmaker Novo Nordisk is working on a more ...

Novo Nordisk's CEO is not worried about blockbuster semaglutide drugs being added to Medicare drug pricing negotiations this ...